서울대학교(SNU) 세포주 수립에 관한 연구:1989 년 11 월 ~ 1990 년 8 월

이상은,이한구,이상훈,김승욱,김진복,허대석,박재갑,김주현,김수태,이은식,김영균,이종욱,김용일,김광현,최규완,박성회,최황,이건욱,박규주,김정룡,양한광,성숙환,강순범,이효표,안효섭,최국진,최영민,박용현,오승근,한대희,정희원,김노경,방영주,김현집,신희철,김병국,노동영,박선양,박명희,김선회,민양기,고창순,김시황,왕규창,유영석,전유미 대한암학회 1991 Cancer Research and Treatment Vol.23 No.2

$quot;Thirty eight human cancer cell lines have been established (success rate 18.4%) from 206 tumor specimens from November 1989 to August 1990 at Laboratory of Tumor Cell Biology, Cancer Research Institute, Seoul National Vniversity College of Medicine. We used AR5 media (ACL-4 media in RPMI-1640 plus 5% FBS) for routine culture for all tumor cells except gastric cancers. R10 media (RPMI-1640 plus 10% FBS) was used for gastric cancer. Thyroid stimulating hormone (TSH) was added to AR5 for thyroid cancer. Established cancer cell lines are 1 gastric adenocarcinoma, 3 colorectal adenocarcinoma, 7 he- patocellular carcinoma, 2 breast ductal carcinoma, 7 renal cell carcinoma, 4 transitional cell carcinoma of urinary bladder, 2 glioblastoma multiforme, 1 oligodendroglioma, 1 gallbladder carcinoma, 2 pancreatic adenocarcinoma, 3 Wilms' tumor, 1 lung cancer, 1 thyroid papillary cancer, 1 ovarian cancer, 1 ampulla of Vater adenocarcinoma and 1 metastatic squamous cell carcinoma of thigh. Another hepatocellular carcinoma line (SNU-182) initiated in June 1989 was established after 16 months. AR5 media was useful especially for establishment of cell lines fram hepatocellular carcinoma (success rate 36.8% [7/19]), pancreatic cancer (success rate 100% [2/2]):.glioblastom.a multiforme (success rate 100% [2/2]) and urologic cancers such as renal cell carcinoma (success rate 46.7% [7/ 15]), transitional cell carcinoma of urinary bladder (success rate 33.3% [4/12]), and Wilms tumor (success rate 75.0% (3/4)).$quot;

Linking Human Papillomavirus to Cervical Cancer

Lee,,Hyo,Pyo MediMedia Korea 1996 JAMA-Korea Vol.11 No.2

Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer-Trial of Intra-Arterial Chemotherapy

( Hyo Pyo Lee ) 대한산부인과학회 1996 서울심포지움 Vol.3 No.-

성장인자 및 성장 호르몬 첨가 배지를 이용한 SNU 세포주 수립에 관한 연구

이상은,이한구,이상훈,김승욱,김진복,허대석,박재갑,김주현,김수태,김영균,이종욱,김용일,김광현,박성회,이건욱,홍인규,성숙환,강순범,이효표,안효섭,최국진,최영민,박용현,오승근,한대희,정희원,김노경,방영주,김현집,신희철,노동영,박선양,박명희,홍성국,고창순,김시황,권남숙,허버트오이,아디가즈다,왕규창,유영석 대한암학회 1990 Cancer Research and Treatment Vol.22 No.1

Comparison of Agar and Agarose Culture Methods for Human Tumor Stem Cell Assay of Gynecologic Tumors

Lee,,Hyo,Pyo,Cha,,Sang,Hum Seoul National University 1986 The seoul journal of medicine Vol.27 No.2

Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer-Trial of Intra-Arterial Chemotherapy

Lee,,Pyo,Hyo 中央醫學社 1996 中央醫學 Vol.61 No.10

Background & Aims : In the last few years, neoadjuvant chemotherapy has been applied as a new therapeutic approach in the treatment of cervical cancer. Even though survival benefit is still controversial, a subset of patients with chemoresponse may have increased survival rate. We have evaluated the efficacy of intra -arterial neoadjuvant chemotherapy in locally advanced and/ or bulky cervical cancer. Methods : Twenty - four patients with carcinoma of the uterine cervix - I b/IIa with to nor greater than 5 cm in largest diameter or stage IIb/III disease -were enrolled in our study. Intra - arterial chemotherapy consisted of catheterization of the uterine artery using mitomycin - C, 10 mg/m2 ; vincristine, 1 mg/m2 ; and cisplatin, 75 mg/m2(MVP). Patient's response were evaluated with clinical examination and colposcopy before and 2?3 weeks after each chemotherapy cycles. Computerized tomography or magnetic resonance imaging has been done for tumor size evaluation before starting chemotherepay and just before adopting -a definitive treatment. Results At the end of the chemotherapy, 6 patients(25.0 %) responded completely, 17 patients(70.8 %) partially and 1(4.3 %) not at all. Tumor mass size has decreased from 22.4 cm2 to 3.7 cm2 in average(reduction rate=83.5 %). No chemotherapy related complication was so severe that treatment had to be discontinued except one case of necrotizing cystitis. Type III radical hysterectomy was performed in 18 patients(75 %) and five patients showed pathological complete response(27.8 %, 5/18). Lymph node metastases were found only in 4 patients(22.2 %, 4/18). Median follow-up time is 15 months(range, 8 to 27 months) now and 22 patients have no evidence of disease and two patients(8.3 %) showed recurrent disease. Conclusion Intra-arterial combination chemotherpay with MVP could be effective against advanced and primarily inoperable cervical cancer with bulky mass. A search for more safe infusion

Analysis of Prognostic Factors Affecting Survival in Stage 1b Carcinoma of Cervix Treated by Radical Pelvic Surgery with and without Post-operative Radiotherapy

( Hyo Pyo Lee ), ( Geung Hwan Ahn ) 대한산부인과학회 1983 대한산부인과학회 학술대회 Vol.51 No.-

최신임상강좌 : 한국 부인암의 현황: 1991~2004년까지의 동향

이효표 ( Hyo Pyo Lee ) 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.12

대한산부인과학회 산하의 부인종양위원회가 1989년 설립된 후로 부인암 등록사업이 시작되었고, 이후 2004년도까지 1~2년 간격으로 총 12회에 걸쳐 시행되었으며, 현재 2005년도 및 2006년도 자료에 대한 부인암 등록사업이 진행 중이다. 부인암 등록사업의 목적은 우리나라 여성에서 발생하는 부인암의 발생 빈도를 정확히 파악하여 향후 부인암 연구의 기본 자료로 활용하고자 함이며, 나아가 치료 성적 및 생존율에 관한 체계적인 통계 자료를 구축하고자 함이었다. 부인암 등록사업의 특징은 보건복지부에서 매년 시행하고 있는 한국중앙암등록사업의 국민 암발생 빈도와 추세를 파악하는 것에 나아가서, 환자의 산과력 및 과거력 등을 기입하여 세 종류의 부인암, 즉 자궁경부암, 난소암, 자궁체부암에 대한 기본적 역학 조사를 시행함으로써 각 질환의 위험 인자를 분석하고자 하였으며, 정확한 조직학적 분류 및 병기, 치료 방법 등을 기입하여 이들의 분포를 파악하고, 향후 추적 조사에 의해 각 치료법에 따른 치료 성적 및 생존율을 분석하고자 하였다. 이번 보고서에서는 지금까지 시행되었던 부인암 등록사업을 총괄하여 1991년부터 2004년까지의 부인암의 발생 동향 및 각각의 암에서의 생존율을 분석하였다. Korean Society of Obstetrics and Gynecology estimates the number of new gynecologic cancer cases and deaths expected in Korea in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the Gynecologic Cancer Registry Program every one or two years. Recently, gynecologic cancer registry gathering clinical data in 2005~2006 is in progress. In this article, we provide an overview of cancer statistics, including recent trends in gynecologic cancer incidence, mortality, and survival rates from 1991 through 2004.

재발성 자궁경부암의 임상 양상 및 예후에 관한 연구

이승호 ( Seung Ho Lee ), 이유경 ( Yoo Kyung Lee ), 김희승 ( Hee Seung Kim ), 김재원 ( Jae Won Kim ), 박노현 ( Noh Hyun Park ), 송용상 ( Yong Sang Song ), 강순범 ( Soon Beom Kang ), 이효표 ( Hyo Pyo Lee ) 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.2

진행성 또는 재발성 자궁경부암에서 Cislatin, Vincristine, Bleomycin, Methotrexate(PVBM) 복합화학요법

박영석,김승욱,허대석,김효진,이기형,강순범,이효표,이진용,김노경,서창인,방영주,하성환,강원기,임영혁,박찬일,김홍태 대한암학회 1990 Cancer Research and Treatment Vol.22 No.3

Twenty-nine patient with advanced cervix cancer were treated with a combination chemotherapy of cisplatin, vincristine, bleomycin, and methotrexate between January, 1987 and December, 1988. 1) Among 19 evaluable patients, 4 patients (20.1%) achieved complete response and 6 patients (31. 6%) achieved partial response, giving an overall response rate of 51.7%. The median duration of remission was 23 weeks in the responders. 2) The median survival of overall patients was 50 7 weeks. The median survival of the responders did not reach the median value during the follow-up period of 15-81 weeks. In contrast, the median survival of the non-responders was 30.7 weeks, which was significantly shorter than that of the responders (p$lt;0.05). 3) The only factor influencing remission rate was the pattem of failure, and the patients with distant metastasis showed higher remission rates (p$lt;0.01). There were no prognostic factors influencing the remission duration. The factors improving survival rates were the early stage at diagnosis (p$lt; 0. 005), the previous history of curative operation (p$lt;0.005), and the presence of distant metastasis (p$lt;0.01). 4) Considerable number of patients experienced toxicities. Among these, leukopenia (50%) and thrombocytopenia (4.7%) were the main hematologic toxicities. Most patients experienced nausea, vomiting, diarrhea (89.49o), stomatitis (26 3%), and alopecia (73.7%). Neurotoxicity due to vincristine or cispatin was found in 36.896 of patients, and 2 patients showed pulmonary fibrosis due to bleomycin toxicity. In conclusion, this regimen (PVBM) seems to be effective in terms of remission rates, but did not show any additional benifits in terms of remission duration or overall survival. In addition, the large number of patients experienced considerable side effects. Based on these findings, further studies are needed to find out the new regimen which is more effective and less toxic for the patients with advanced uterine cervix cancer.